AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has met prespecified targets in a phase 2 trial the companies said on Monday.
Positive high-level results from an analysis of the ongoing trial showed Enhertu met the prespecified target for objective response rate and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pre-treated patients.
The trial is evaluating the efficacy and safety of Enhertu in patients with locally advanced, unresectable, or metastatic previously treated, HER2-expressing solid tumours not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and rare cancers.
It is already in use for patients with HER2-targetable breast, gastric and lung cancers.
Reporting by Frank Prenesti for Sharecast.com
